| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/30/2002 | WO2002042265A2 Cyanoguanidine prodrugs |
| 05/30/2002 | WO2002042248A2 Naphthalene derivatives |
| 05/30/2002 | WO2002041918A2 Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage |
| 05/30/2002 | WO2002041915A1 A composition of sodium channel blocking compound |
| 05/30/2002 | WO2002041910A2 Methods and compositions for the treatment of diseases of the eye |
| 05/30/2002 | WO2002041904A1 Method for treating hiv |
| 05/30/2002 | WO2002041901A1 Treatment of osteoporosis |
| 05/30/2002 | WO2002041899A1 An antibiotic/analgesic formulation and a method of making this formulation |
| 05/30/2002 | WO2002041897A2 Novel pharmaceutical compositions with anti-diabetic activity and method for preparing same |
| 05/30/2002 | WO2002041894A2 Selective dopamine d4 receptor agonists for treating sexual dysfunction |
| 05/30/2002 | WO2002041893A1 Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers |
| 05/30/2002 | WO2002041891A2 Hiv treatment with benzimidazoles |
| 05/30/2002 | WO2002041890A1 Medicinal compositions |
| 05/30/2002 | WO2002041884A2 Inhibitors of abc drug transporters at the blood-brain barrier |
| 05/30/2002 | WO2002041883A2 As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation |
| 05/30/2002 | WO2002041882A2 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 05/30/2002 | WO2002041879A2 Antidiabetic compositions containing a biguanide and a sulfonamide |
| 05/30/2002 | WO2002041871A2 Composition comprising an imexon or derivatives thereof and lipids |
| 05/30/2002 | WO2002041837A2 Treatment of mucositis |
| 05/30/2002 | WO2002041827A2 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 05/30/2002 | WO2002028440B1 Methods and compositions for modulating t cell activation and uses thereof |
| 05/30/2002 | WO2002020736A9 Proteases |
| 05/30/2002 | WO2002018581A9 G-protein coupled receptors |
| 05/30/2002 | WO2002011550A3 Oil/fat composition |
| 05/30/2002 | WO2002009643A3 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| 05/30/2002 | WO2002005792A3 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 05/30/2002 | WO2002000254A3 Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| 05/30/2002 | WO2001095928A3 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 05/30/2002 | WO2001094380A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 05/30/2002 | WO2001092274A3 Naaladase inhibitors for treating retinal disorders and glaucoma |
| 05/30/2002 | WO2001091789A3 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 05/30/2002 | WO2001091737A3 Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
| 05/30/2002 | WO2001089495A3 Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose |
| 05/30/2002 | WO2001087979A3 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| 05/30/2002 | WO2001087934A3 Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides |
| 05/30/2002 | WO2001087913A3 Method for treating retinal degeneration with purinergic receptor agonists |
| 05/30/2002 | WO2001087330A3 Compositions and methods for achieving immune suppression |
| 05/30/2002 | WO2001081413A3 Isolated human transporter proteins, nucleic acids and uses thereof |
| 05/30/2002 | WO2001078700A3 Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine |
| 05/30/2002 | WO2001074780A8 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist |
| 05/30/2002 | WO2001074390A3 The use of a calcium channel blocker for treating renal disorders |
| 05/30/2002 | WO2001068704A3 G-protein coupled receptors |
| 05/30/2002 | WO2001068679A3 Peptides targeting specifically tumor-derived endothelial cells |
| 05/30/2002 | WO2001064877A3 Human schizophrenia gene |
| 05/30/2002 | WO2001060278A3 Oral therapeutic delivery appliance |
| 05/30/2002 | WO2001051043A3 Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
| 05/30/2002 | WO2001041741A9 Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| 05/30/2002 | WO2001023405A3 Therapeutic treatment of androgen receptor driven conditions |
| 05/30/2002 | WO2001016300A3 Method of identifying inhibitors of cdc25 |
| 05/30/2002 | WO2000078952A8 Human rna metabolism proteins (rmep) |
| 05/30/2002 | WO2000066225A8 Contraceptive compositions containing cyclic carbamates and amide derivatives |
| 05/30/2002 | WO2000060953A3 Methods for stabilizing liquid nutritional products and products so stabilized |
| 05/30/2002 | WO2000013684A3 Pharmaceutical composition and method for treatment of inflammation |
| 05/30/2002 | US20020065395 Polypeptide for use as diagnostic tool in screening bactericides |
| 05/30/2002 | US20020065393 Human hypoxanthine- (guanine) phosphoribosy1 transferase-2 |
| 05/30/2002 | US20020065327 Pharmaceutically active compounds and methods of use thereof |
| 05/30/2002 | US20020065321 Nasal administration of agents for the treatment of gastroparesis |
| 05/30/2002 | US20020065302 Cyclic AMP-specific phosphodiesterase inhibitors |
| 05/30/2002 | US20020065292 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity |
| 05/30/2002 | US20020065284 Dipeptide derivatives |
| 05/30/2002 | US20020065278 Non-imidazole aryloxyalkylamines |
| 05/30/2002 | US20020065277 Administering to an obese patient or a patient at risk of becoming obese therapeutically effective amount of compound that attenuates binding of agouti-related protein to melanocortin receptors |
| 05/30/2002 | US20020065272 Olanzapine-N-oxide compositions and methods |
| 05/30/2002 | US20020065266 Bicyclic or tricyclic ketones, oximes, amine oxides or amines are used as calcium or potassium channel modulators |
| 05/30/2002 | US20020065259 Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| 05/30/2002 | US20020065247 Triarylmethane derivatives having inhibitory activity on an intermediate conductance Calcium ion activated potassium channel (IKCa) |
| 05/30/2002 | US20020065244 Method of treating dry eye disease with purinergic receptor agonists |
| 05/30/2002 | US20020065241 A recombinant polynucleotide of first polynucleotides coding an antigenic peptide and are operatively linked to each other to enhance translation of the polynucleotides to the peptides and binding to MHC; cancer vaccine |
| 05/30/2002 | US20020065238 EPO primary response gene, EPRG3pt |
| 05/30/2002 | US20020065229 Anti-S-phase tubulin ligands |
| 05/30/2002 | US20020065220 For use in diagnosis and therapy of disorders treating disorders related to these novel human immunoglobulin-like (Ig- like) proteins |
| 05/30/2002 | US20020065214 Method of treating congestive heart failure |
| 05/30/2002 | US20020064856 Novel proteases |
| 05/30/2002 | US20020064851 Peptide for use in development of human diagnostics and therapeutics; for use in deection and treatment of cancer, inflammation, immune disorders and development defects |
| 05/30/2002 | US20020064848 Novel histidinol dehydrogenase |
| 05/30/2002 | US20020064843 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/30/2002 | US20020064826 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |
| 05/30/2002 | US20020064821 Isolated human ion channel proteins, nucleic acid molecules encoding human ion channel proteins, and uses thereof |
| 05/30/2002 | US20020064785 Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
| 05/30/2002 | US20020064784 Monitoring drug binding activity; obtain cells, generate mutation in cell genome, detect killing mutation, recover protein generated |
| 05/30/2002 | US20020064560 Hydrophobic and/or hydrophilic active agents and a polymeric emulsifier. |
| 05/30/2002 | US20020064554 Radiation sensitive liposomes |
| 05/30/2002 | US20020064540 Composition, particularly cosmetic, combining DHEA and/or a precursor or derivative thereof, and at least an agent for increasing glycosaminoglycan synthesis |
| 05/30/2002 | US20020064536 Immobilizing a mammal by administering the toxin with a polysaccharide stabilizer, nonimmunogenic; use after surgery such as hip displasia or to recover from leg injuries in domestic animals |
| 05/30/2002 | US20020064527 Administering agents that hinder CD30/CD30L (CD30L=ligand of CD30) binding; animal model of arthritis for drug screening |
| 05/30/2002 | US20020064503 Administering dose of mixture of lipid crystals comprising surfactant and spreading agnet as aerosol through an external airway of a mammal for enhancing mammalian eustachian tube lumen patency and pressure equalization performance |
| 05/30/2002 | US20020063763 Apparatus and method for removing air bubbles from an ink jet printhead |
| 05/30/2002 | US20020062835 Methods of modulating hair growth |
| 05/30/2002 | CA2434760A1 Differentiated cells suitable for human therapy |
| 05/30/2002 | CA2431947A1 Composition comprising an imexon or derivatives thereof and lipids |
| 05/30/2002 | CA2430202A1 Method for treating hiv |
| 05/30/2002 | CA2430037A1 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| 05/30/2002 | CA2429817A1 Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 05/30/2002 | CA2429712A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 05/30/2002 | CA2429699A1 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 05/30/2002 | CA2429630A1 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 05/30/2002 | CA2429605A1 Indol derivative and their use as inhibitors of p38 kinase |
| 05/30/2002 | CA2429579A1 Truncated cd200 |
| 05/30/2002 | CA2429576A1 Fungal gene cluster associated with pathogenesis |
| 05/30/2002 | CA2429516A1 As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation |